ADMA Biologics Faces Class Action Lawsuit Over Allegations of Securities Fraud
ADMA Biologics Faces Class Action Lawsuit Over Allegations of Securities Fraud
On August 10, 2026, a significant legal development unfolded for investors of ADMA Biologics, Inc. (NASDAQ: ADMA) as Hagens Berman Sobol Shapiro LLP issued a notice regarding a class action lawsuit focused on alleged securities fraud. This lawsuit accuses ADMA Biologics of misrepresenting critical aspects of its financial condition, revenue generation processes, and overall business practices.
Overview of the Lawsuit
The claims stem from allegations that ADMA Biologics artificially inflated its stock prices by concealing negative information regarding its operations. Investors have been cautioned that they may have suffered considerable financial losses as a result of these misleading statements. Key points of contention include:
- - Undisclosed related party transactions.
- - The practice of channel stuffing to create an illusion of increased revenue.
- - Ineffective internal controls that could have mitigated fraud risks.
This lawsuit encompasses actions that took place from August 9, 2024, to March 25, 2026, and legal representatives stress the urgency for potential claimants to respond promptly. The deadline for lead plaintiffs to apply is notably set for August 10, 2026.
Implications for ADMA Investors
The implications of these allegations are severe. The lawsuit claims that upon the revelation of these misrepresentations—particularly through corrective disclosures initiated by Culper Research—ADMA's stock experienced dramatic declines. On March 24, 2026, a report was published that unveiled several concerning practices, resulting in a staggering 31.6% drop in stock value over just two days. Such impactful corrections have placed shareholders in a precarious financial state, further exacerbating their losses.
In a subsequent press release, ADMA attempted to reassure investors by stating they remained committed to addressing the findings put forth by Culper Research. However, this was met with further negative sentiments, as a stock downgrade from Cantor Fitzgerald led to another 13.9% decline in share prices, solidifying the concerns surrounding the company's financial management.
Next Steps for Affected Investors
For those affected by these recent developments, Hagens Berman is actively seeking individuals who may provide insight or corroborate claims pertaining to the class action suit. They urge any investors who saw substantial losses during the class period to contact their office. Those with additional information that could assist in the investigation are encouraged to reach out via phone or email.
Whistleblower Information
In light of this situation, whistleblowers with non-public information about ADMA Biologics may find guidance through the SEC Whistleblower Program, offering rewards for valuable information leading to enforcement actions. This program underscores the importance of corporate accountability and encourages individuals to come forward with crucial evidence.
Conclusion
ADMA Biologics, Inc. now stands at a critical juncture. The outcomes of the ongoing class action lawsuit will significantly impact its future trajectory and that of its investors. It serves as a sobering reminder of the need for transparency in corporate operations. Investors are advised to stay alert for further developments as Hagens Berman leads the investigation into these troubling allegations.
For more detailed information, prospective class members can visit Hagens Berman's official site
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.